IP Library Granted Patent US 8,153,689
Granted Patent B2
US 8,153,689 · App. 13/252,732 · Granted Apr 10, 2012

Pleuromutilin derivatives for the treatment of diseases mediated by microbes

Assignee: Nabriva Therapeutics AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,689
App. No.
13/252,732
Granted
Apr 10, 2012
Kind
B2
Abstract

Disclosed are pleuromutilin derivatives of formula (I) and their use in the treatment of diseases mediated by microbes.

Claims (5)

1. A composition comprising the compound 14-O-{[(1R, 2R, 4R)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin, wherein said compound has the structure of formula (I):

2. The composition of claim 1 in the form of a pharmaceutically acceptable salt.

3. The composition of claim 2 wherein said salt is selected from the group consisting of a sodium salt, a potassium salt, a calcium salt, a magnesium salt, trimethylammonium salt, an isopropylamine salt, a diethylamine salt, an ethanolamine salt, a trimethylamine salt, a dicyclohexyl amine salt, a N-methyl-D-glucamine salt, a hydrogen fumaric acid salt, a fumaric acid salt, a tartaric acid salt, an ethane-1,2-disulphonic acid salt, a naphthalin-1,5-sulphonic acid salt, an acetic acid salt, a maleic acid salt, a succinic acid salt, a salicylic acid salt, an azelaic acid salt, a 2-[(2,6-dichlorophenyl)amino]benzene acetic acid salt, and a hydrochloric acid salt.

4. The composition of claim 1 , further comprising at least one pharmaceutically acceptable excipient.

5. The composition of claim 2 , further comprising at least one pharmaceutically acceptable excipient.

Assignments (10)
NUNC PRO TUNC ASSIGNMENT Recorded Apr 3, 2025
From: NABRIVA THERAPEUTICS GMBH
To: HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD.
Reel/Frame 070725/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2025
From: NABRIVA THERAPEUTICS GMBH
To: HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD.
Reel/Frame 069806/0458 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA AND THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 062881 FRAME: 0090. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Jun 20, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 064312/0350 →
RELEASE OF SECURITY INTEREST Recorded Mar 3, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH; ZAVANTE THERAPEUTICS, INC.
Reel/Frame 062881/0090 →
SECURITY INTEREST Recorded Jan 18, 2019
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 048062/0807 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 20, 2018
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 047973/0110 →
CHANGE OF NAME Recorded Jul 18, 2018
From: NABRIVA THERAPEUTICS AG
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 047958/0106 →
RELEASE OF SECURITY INTEREST Recorded Sep 29, 2016
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 039894/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2014
From: NABRIVA THERAPEUTICS AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 033935/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2012
From: MANG, ROSEMARIE; HEILMAYER, WERNER; BADEGRUBER, RUDOLF; STRICKMANN, DIRK B.; NOVAK, RODGER; FERENCIC, MATHIAS; BULUSU, ATCHYUTA RAMA CHANDRA MURTY
To: NABRIVA THERAPEUTICS AG
Reel/Frame 027745/0615 →
Priority Claims (1)
EP 07450053 · Mar 20, 2007 · regional
Continuity (2)
Continuation 12531839
Related Publication 20120029072A1 · Feb 2, 2012